{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:41:19Z","timestamp":1777714879372,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Psychiatry Med"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the efficacy of escitalopram combined with quetiapine vs quetiapine alone in the treatment of depressive episodes of bipolar disorder (BPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty-eight hospitalized patients with a BPD depressive episode were recruited into the study. All patients were randomized to a control group (n = 44) or the intervention group (n = 44). Members of the control group received quetiapine fumarate alone, with an initial dose 50 mg twice\/day; the dose was increased by 50-100 mg daily until 300-600 mg\/d was reached. The treatment group received quetiapine at the same doses plus escitalopram, with the initial dose of escitalopram 10 mg\/d, adjusting the dose to 20 mg\/d after 1 week. Both groups were treated for 8 weeks. Scores on the Hamilton Depression Scale (HAMD) and Young Mania Rating Scale (YMRS), along with levels of IL-6, IL-1\u03b2, MIF, SOD, CAT, MDA and GSH-Px, were compared between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among those in the intervention group, 88.6% of participants experienced a 50% or greater reduction in HAMD score compared to 70.5% in the control group (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .05). Participants in the intervention group also experienced a significantly greater reductions in IL-6, IL-1\u03b2, MIF and MDA levels (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .05), and a significant increase in SOD, CAT and GSH-Px levels compared to the control group (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Escitalopram oxalate combined with quetiapine is more effective than quetiapine alone in the treatment of patients with bipolar depressive episodes. This combination can effectively improve the symptoms of depression, inhibit the body\u2019s inflammatory response, regulate the state of oxidative stress, and does not increase the risk of mania.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00912174251316653","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T18:01:16Z","timestamp":1738864876000},"page":"624-636","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Quetiapine combined with escitalopram in the treatment of bipolar depression"],"prefix":"10.1177","volume":"60","author":[{"given":"Pingping","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, The Third People\u2019s Hospital of Ganzhou, Ganzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinchang","family":"Huang","sequence":"additional","affiliation":[{"name":"Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Bipolar Disorde, Shenzhen Kangning Hospital, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, The Third People\u2019s Hospital of Ganzhou, Ganzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2069-3777","authenticated-orcid":false,"given":"Haiying","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ganzhou Fifth People\u2019s Hospital, Ganzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13269"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2020.12.031"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-023-00440-7"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.09.063"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291718002854"},{"issue":"4","key":"e_1_3_4_7_2","first-page":"31","article-title":"A randomized, double-blind, controlled clinical trial of omega-3 fatty acids and inositol as monotherapies and in combination for the treatment of pediatric bipolar spectrum disorder in children age 5-12","volume":"52","author":"Wozniak J","year":"2022","unstructured":"Wozniak J, Farrell A, DiSalvo M, et al. A randomized, double-blind, controlled clinical trial of omega-3 fatty acids and inositol as monotherapies and in combination for the treatment of pediatric bipolar spectrum disorder in children age 5-12. Psychopharmacol Bull. 2022;52(4):31-51.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.616415"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0044-2"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2181-9"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.08.096"},{"key":"e_1_3_4_12_2","first-page":"109","article-title":"Phenothiazines and related antipsychotic drugs","volume":"2","author":"Rashid M","year":"2020","unstructured":"Rashid M, Rahman M, Khan MF. Phenothiazines and related antipsychotic drugs. Med Chem of Drugs Aff the Nervous Sys. 2020;2:109-162.","journal-title":"Med Chem of Drugs Aff the Nervous Sys"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000015"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2021.08.264"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000440"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2023.114613"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.158"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.2c00420"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.06.050"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2021.20091339"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001601"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.0031"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17020241"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.0039"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123990"},{"issue":"3","key":"e_1_3_4_26_2","first-page":"1905","article-title":"Effects of escitalopram oxalate plus low-dose trazodone on psychological state and quality of life in patients with treatment-refractory depression","volume":"15","author":"Zhang X","year":"2023","unstructured":"Zhang X, Ma X, Cheng W, et al. Effects of escitalopram oxalate plus low-dose trazodone on psychological state and quality of life in patients with treatment-refractory depression. Am J Transl Res. 2023;15(3):1905-1912.","journal-title":"Am J Transl Res"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169103"},{"key":"e_1_3_4_28_2","volume-title":"Sertraline and Escitalopram in First Episode of Unipolar Depressive Disorder","author":"Divyashree C","year":"2019","unstructured":"Divyashree C. A comparative study of efficacy and safety of fluoxetine. In: Sertraline and Escitalopram in First Episode of Unipolar Depressive Disorder. Bengaluru, India: Rajiv Gandhi University of Health Sciences; 2019."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2854"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21170-y"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/PRA.0000000000000660"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2014.04.005"}],"container-title":["The International Journal of Psychiatry in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00912174251316653","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00912174251316653","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00912174251316653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:13:09Z","timestamp":1777457589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00912174251316653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/00912174251316653"],"URL":"https:\/\/doi.org\/10.1177\/00912174251316653","relation":{},"ISSN":["0091-2174","1541-3527"],"issn-type":[{"value":"0091-2174","type":"print"},{"value":"1541-3527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}